Factors Associated with Inadequate Response to MDD Treatment
References
Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157(2):229-33.
Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959-85.
Weinberger MI, Sirey JA, Bruce ML, Heo M, Papademetriou E, Meyers BS. Predictors of major depression six months after admission for outpatient treatment. Psychiatr Serv. 2008;59(10):1211-5.
Lythe KE, Moll J, Gethin JA, et al. Self-blame–selective hyperconnectivity between anterior temporal and subgenual cortices and prediction of recurrent depressive episodes. JAMA Psychiatry. 2015;72(11):1119-1126.
Skodol AE, Grilo CM, Keyes KM, Geier T, Grant BF, Hasin DS. Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample. Am J Psychiatry. 2011;168(3):257-64.
Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62. Suppl 16:5-9.
American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. American Psychiatric Association; 2010.
Schueller SM, Kwasny MJ, Dear BF, Titov N, Mohr DC. Cut points on the Patient Health Questionnaire (PHQ-9) that predict response to cognitive-behavioral treatments for depression. Gen Hosp Psychiatry. 2015;37(5):470-475
McIntyre R, Kennedy S, Bagby RM, Bakish D. Assessing full remission. J Psychiatry Neurosci. 2002;27(4):235-9.
Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841-1853.
Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother. 2009;9(7):975-984.
American Psychological Association. Clinical practice guideline for the treatment of depression across three age cohorts. 2019. Updated October 2021. https://www.apa.org/depression-guideline.apa.org/depression-guideline
Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-1504.
Buckman JEJ, Underwood A, Clarke K, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis. Clin Psychol Rev. 2018;64:13-38.
This resource is intended for educational purposes only and is intended for US health care professionals. Health care professionals should use independent medical judgment. All decisions regarding patient care must be handled by a health care professional and be made based on the unique needs of each patient.
ABBV-US-01064-MC, Version 2.0
Sponsored by AbbVie Medical Affairs
Approved 04/2023
Recommended on NP Psych Navigator

NP Spotlights
NP Spotlight: Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN
A career as a psychiatric nurse practitioner can be replete with challenges and opportunities. The NP Psych Navigator Spotlight is your chance to learn more about nurse practitioners who are working to advance the profession and mental health in general. In this installment of this series, we profile Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN.

Clinical Article
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-term Outcomes of a Single-blind Randomized Study
Major depressive disorder (MDD) is a chronic and disabling condition that affects up to 12% of men and 25% of women. MDD is recurrent, with many patients not achieving complete recovery between depressive episodes. The aim of treatment for MDD is remission, which is associated with improved functioning and prognosis.

Clinical Article
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder (MDD) Unresponsive to Antidepressant Treatment: the VAST-D Randomized Clinical Trial
Major depressive disorder (MDD) is a chronic condition that affects millions of Americans. Unfortunately, first-line monotherapy does not adequately address depressive symptoms for some MDD patients. The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial set out to determine the relative effectiveness and safety of 3 next-step treatments for MDD in patients who failed to respond adequately to at least 1 antidepressant treatment trial of adequate dose and duration. This clinical article summary shares the key findings of this landmark trial.